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Discussion
Dr David R. Jones (Charlottesville, Va). I congratulate you on a
nice presentation.
You hypothesized that gossypol would enhance Apo2L and
TRAIL-mediated apoptosis through its ability to inhibit Bcl2 and
perhaps BclXL. Do you have any evidence that this is indeed the
pathway? For instance, have you performed any siRNA experi-
ments with either Bcl2 or BclXL that would be more confirmatory
of your hypothesis?
Second, gossypol has been shown to increase both Fas and Fas
ligand expression, which has been suggested to account for at least
75% of apoptosis in certain non–small cell lung cancer cell lines.
Do you think this may be the mechanism through which gossypol
is truly working, and, if not, why not?
Finally, if you believe you can move this preclinical data
toward a phase 1 trial, can you tell us whether there are any
combined or additive toxicities of these two biologic agents?
Dr Yeow. Thank you, Dr. Jones.
To answer your first question, gossypol inhibiting Bcl2/BclXL,
it has not been shown by us but it has been shown by previous
authors using colon carcinoma that gossypol does interact as a
BH3 mimetic, does bind to the pocket of Bcl2/BclXL. They
showed it through one assay that demonstrates that if two proteins
come together, there is fluorescence. They were also able to show
it in another one using x-ray crystallography. Thus it has been
shown that gossypol will bind to the pocket.
Second, in terms of gossypol affecting 70% of non–small cell
lung carcinomas and that being the sole agent, we are using a
concentration of gossypol that does not do that. We are aiming for
suboptimal doses, and we are using suboptimal doses of both
gossypol and TRAIL. We hope that they will combine and selec-
tively target the cancer cells.
Third, the ability to take it to a phase 1 trial, the gossypol that
we are using is a mix of positive and negative enantiomers, and it
is not as potent as the negative enantiomer, which is the agent that
has been taken to clinical trials. There is a better secondary,
tertiary, third generation of gossypol that could potentially be
taken to clinical trials. We do not anticipate gossypol as a mix to
be taken there at that level.
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